<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439189</url>
  </required_header>
  <id_info>
    <org_study_id>CON-EX-0616</org_study_id>
    <nct_id>NCT03439189</nct_id>
  </id_info>
  <brief_title>Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14</brief_title>
  <official_title>Companion Protocol for the ¹³C-Methacetin Breath Test Using the BreathID® MCS System for Conatus Phase 2 Study of Emricasan, an Oral Caspase Inhibitor, Under Protocol IDN-6556-14 (NCT02960204)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exalenz Bioscience LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conatus Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Exalenz Bioscience LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To validate the ability of the Methacetin Breath Test (MBT) to detect clinically significant&#xD;
      portal hypertension (CSPH)/severe portal hypertension (SPH) defined as hepatic venous&#xD;
      pressure gradient (HVPG) ≥ 10 mmHg and HVPG ≥ 12 mmHg respectively, in patients with&#xD;
      non-alcoholic steatohepatitis (NASH) during the course of treatment with Conatus's&#xD;
      investigational product emricasan/placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a companion protocol that will use the data generated by Conatus' study of&#xD;
      emricasan under protocol IDN-6556-14 (NCT02960204).The IDN-6556-14 study is a Phase 2,&#xD;
      multicenter, double-blind, randomized, placebo-controlled trial in subjects with&#xD;
      non-alcoholic steatohepatitis (NASH) cirrhosis and severe portal hypertension.&#xD;
&#xD;
      As one of the Conatus' study exploratory objectives, this companion protocol is designed to&#xD;
      assess whether emricasan compared to placebo improves liver metabolic function at Weeks 24&#xD;
      and 48 as assessed by the methacetin breath test (at select sites), if relevant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2016</start_date>
  <completion_date type="Actual">May 13, 2019</completion_date>
  <primary_completion_date type="Actual">April 8, 2019</primary_completion_date>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The population performing the MBT at weeks 24 and 48 will have approximately an equal number of subjects from each of the 4 parallel treatment arms (5 mg, 25 mg, 50 mg or placebo).</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The collaborator is responsible for the masking process.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Matched Clinically Significant Portal Hypertension Based on Hepatic Venous Pressure Gradient (HVPG) and Methacetin Breath Test (MBT)</measure>
    <time_frame>1 hour for MBT related to assessment of this diagnostic primary outcome assesses during screening</time_frame>
    <description>Binary diagnosis of clinically significant portal hypertension (CSPH) as determined by HVPG, defined as HVPG ≥ 10mmHg and by the MBT derived from an algorithm developed under other Exalenz clinical studies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Matched Subjects With Significant Portal Hypertension (Defined as HVPG&gt;=12mmHg) Based on HVPG and MBT</measure>
    <time_frame>1 hour for MBT for assessment of this diagnostic secondary outcome assessed during screening</time_frame>
    <description>Binary diagnosis of HVPG&gt;=12mmHg and by the MBT derived from an algorithm developed under other Exalenz clinical studies</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">343</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <condition>Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Emricasan 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (5 mg) twice a day. The MBT will be performed at screening, at week 24/week 48/at early termination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Emricasan 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (25 mg) twice a day. The MBT will be performed at screening, at week 24/ week 48/ at early termination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Emricasan 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (50 mg) twice a day. The MBT will be performed at screening, at week 24/ week 48/ at early termination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with a matching placebo twice a day. The MBT will be performed at screening, at week 24/week 48/at early termination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Methacetin Breath Test</intervention_name>
    <description>A breath analyzer will be used to measure changes in carbon-12 to carbon-13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.</description>
    <arm_group_label>Emricasan 25mg</arm_group_label>
    <arm_group_label>Emricasan 50mg</arm_group_label>
    <arm_group_label>Emricasan 5mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emricasan</intervention_name>
    <description>Investigational drug for NASH treatment in Main Conatus protocol</description>
    <arm_group_label>Emricasan 25mg</arm_group_label>
    <arm_group_label>Emricasan 50mg</arm_group_label>
    <arm_group_label>Emricasan 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo versus emricasan in Conatus NASH treatment trial</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects 18 years or older, able to provide written informed consent&#xD;
             and able to understand and willing to comply with the requirements of the study.&#xD;
&#xD;
          2. Cirrhosis due to NASH with exclusion of other causes of cirrhosis (e.g. chronic viral&#xD;
             hepatitis, alcoholic liver disease, etc.)&#xD;
&#xD;
          3. Compensated cirrhosis OR Decompensated cirrhosis with no more than 1 prior significant&#xD;
             decompensating event.&#xD;
&#xD;
          4. Severe portal hypertension defined as HVPG ≥12 mmHg&#xD;
&#xD;
          5. Subjects who are on NSBB, nitrates, diuretics, lactulose, rifaximin, or statins must&#xD;
             be on a stable dose for at least 3 months prior to Day 1&#xD;
&#xD;
          6. Willingness to utilize effective contraception (for both males and females of&#xD;
             childbearing potential) from Screening to 4 weeks after the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of severe decompensation&#xD;
&#xD;
          2. Severe hepatic impairment defined as a Child-Pugh score ≥10&#xD;
&#xD;
          3. ALT &gt;3 times upper limit of normal (ULN) or AST &gt;5 times ULN during screening&#xD;
&#xD;
          4. Estimated creatinine clearance &lt;30 mL/min&#xD;
&#xD;
          5. Prior transjugular intrahepatic portosystemic shunt or other porto-systemic bypass&#xD;
             procedure&#xD;
&#xD;
          6. Known portal vein thrombosis&#xD;
&#xD;
          7. Symptoms of biliary colic, e.g. due to symptomatic gallstones, within the last 6&#xD;
             months, unless resolved following cholecystectomy, other definitive treatment (e.g.&#xD;
             sphincterotomy), or medical management (e.g. ursodeoxycholic acid)&#xD;
&#xD;
          8. Current use of medications that are considered inhibitors of OATP1B1 and OATP1B3&#xD;
             transporters&#xD;
&#xD;
          9. Alpha-fetoprotein &gt;50 ng/mL&#xD;
&#xD;
         10. History or presence of clinically concerning cardiac arrhythmias, or prolongation of&#xD;
             screening (pre-treatment) QTcF interval of &gt;500 msec&#xD;
&#xD;
         11. History of or active malignancies, other than those successfully treated with curative&#xD;
             intent and believed to be cured&#xD;
&#xD;
         12. Prior liver transplant&#xD;
&#xD;
         13. Change in diabetes medications or vitamin E within 3 months of screening&#xD;
&#xD;
         14. Uncontrolled diabetes mellitus (HbA1c &gt;9%) within 3 months of screening&#xD;
&#xD;
         15. Significant systemic or major illness other than liver disease&#xD;
&#xD;
         16. HIV infection&#xD;
&#xD;
         17. Use of controlled substances (including inhaled or injected drugs) or non-prescribed&#xD;
             use of prescription drugs within 1 year of screening&#xD;
&#xD;
         18. If female: planned or known pregnancy, positive urine or serum pregnancy test, or&#xD;
             lactating/breastfeeding&#xD;
&#xD;
         19. Previous treatment with emricasan or active investigational medication (except&#xD;
             methacetin) in a clinical trial within 3 months prior to Day 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <results_first_submitted>July 21, 2020</results_first_submitted>
  <results_first_submitted_qc>August 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2020</results_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03439189/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects that met the companion protocol eligibility criteria were enrolled.</recruitment_details>
      <pre_assignment_details>Diagnostic endpoints used screening measurements taken prior to study drug administration, therefore no treatment effect was relevant. In addition, for the event prediction endpoints, the treatment covariate was tested for significance, and was found to be non-significant, thus removed from the final predicting model. As such, arms were combined.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ACLD With NASH</title>
          <description>Subjects with advanced chronic liver disease (ACLD) and confirmed nonalcoholic steatohepatitis (NASH)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="343">Subjects performed at least one Methacetin Breath Test (MBT)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="261"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Diagnostic endpoints used screening measurements taken prior to study drug administration, therefore no treatment effect was relevant. In addition, for the event prediction endpoints, the treatment covariate was tested for significance, and was found to be non-significant, thus removed from the final predicting model. As such, arms were combined.</population>
      <group_list>
        <group group_id="B1">
          <title>ACLD With NASH</title>
          <description>Subjects with advanced chronic liver disease (ACLD) and confirmed nonalcoholic steatohepatitis (NASH)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="343"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" spread="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="255"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="316"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.3" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Compensated (Liver disease)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Matched Clinically Significant Portal Hypertension Based on Hepatic Venous Pressure Gradient (HVPG) and Methacetin Breath Test (MBT)</title>
        <description>Binary diagnosis of clinically significant portal hypertension (CSPH) as determined by HVPG, defined as HVPG ≥ 10mmHg and by the MBT derived from an algorithm developed under other Exalenz clinical studies</description>
        <time_frame>1 hour for MBT related to assessment of this diagnostic primary outcome assesses during screening</time_frame>
        <population>Diagnostic endpoints used screening measurements taken prior to study drug administration, therefore no treatment effect was relevant. In addition, for the event prediction endpoints, the treatment covariate was tested for significance, and was found to be non-significant, thus removed from the final predicting model. As such, arms were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With CSPH</title>
            <description>Subjects with Hepatic Venous Pressure Gradient (HVPG) equal to or greater than 10 mmHg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Matched Clinically Significant Portal Hypertension Based on Hepatic Venous Pressure Gradient (HVPG) and Methacetin Breath Test (MBT)</title>
          <description>Binary diagnosis of clinically significant portal hypertension (CSPH) as determined by HVPG, defined as HVPG ≥ 10mmHg and by the MBT derived from an algorithm developed under other Exalenz clinical studies</description>
          <population>Diagnostic endpoints used screening measurements taken prior to study drug administration, therefore no treatment effect was relevant. In addition, for the event prediction endpoints, the treatment covariate was tested for significance, and was found to be non-significant, thus removed from the final predicting model. As such, arms were combined.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Matched Subjects With Significant Portal Hypertension (Defined as HVPG&gt;=12mmHg) Based on HVPG and MBT</title>
        <description>Binary diagnosis of HVPG&gt;=12mmHg and by the MBT derived from an algorithm developed under other Exalenz clinical studies</description>
        <time_frame>1 hour for MBT for assessment of this diagnostic secondary outcome assessed during screening</time_frame>
        <population>Diagnostic endpoints used screening measurements taken prior to study drug administration, therefore no treatment effect was relevant. In addition, for the event prediction endpoints, the treatment covariate was tested for significance, and was found to be non-significant, thus removed from the final predicting model. As such, arms were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Number of Subjects With SPH</title>
            <description>Number of matched subjects with Severe Portal Hypertension (defined as HVPG&gt;=12mmHg) based on HVPG and MBT.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Matched Subjects With Significant Portal Hypertension (Defined as HVPG&gt;=12mmHg) Based on HVPG and MBT</title>
          <description>Binary diagnosis of HVPG&gt;=12mmHg and by the MBT derived from an algorithm developed under other Exalenz clinical studies</description>
          <population>Diagnostic endpoints used screening measurements taken prior to study drug administration, therefore no treatment effect was relevant. In addition, for the event prediction endpoints, the treatment covariate was tested for significance, and was found to be non-significant, thus removed from the final predicting model. As such, arms were combined.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data was collected for a duration of approximately 1 year to observe the effect of the treatment. Additional MBTs after 24 and 48 weeks were performed to enable Conatus to assess the ability of MBT to identify improvement in liver function due to treatment, if relevant. Each MBT duration is 1 hour. The subsequent MBTs were not relevant to companion protocol primary and secondary efficacy diagnostic endpoints listed above, but additional safety information regarding these MBTs was collected.</time_frame>
      <desc>Diagnostic endpoints used screening measurements taken prior to study drug administration, therefore no treatment effect was relevant. In addition, for the event prediction endpoints, the treatment covariate was tested for significance, and was found to be non-significant, thus removed from the final predicting model. As such, arms were combined.</desc>
      <group_list>
        <group group_id="E1">
          <title>ACLD With NASH</title>
          <description>Subjects with advanced chronic liver disease (ACLD) and confirmed nonalcoholic steatohepatitis (NASH)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cramps</sub_title>
                <description>Cramps in the hands. (recorded as possibly related but occurred more than a month after MBT, so unlikely to be related.)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical trial manager</name_or_title>
      <organization>Exalenz Bioscience</organization>
      <phone>00 972 546605412</phone>
      <email>avrahamh@exalenz.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

